U bent hier
Ethics Week 2019 - Lunch Session 2 (Jette) "Gene genius: CRISPR-Cas and gene editing in the lab"
dinsdag, 3 december, 2019 - 13:00
Campus: Brussels Health Campus
R
Atrium/Forum
R
Atrium/Forum
‘Game changer’; ‘disruptor’; ‘spectacular’.
The hype around CRISPR-Cas and gene editing techniques is enormous.
For many researchers, the potential is also real: from ‘fixing’ disease-causing mutations in humans, to making crops more resilient, and managing destructive insects.
However, any technology with great potential brings risks with it: the gene therapy field is still recovering from a clinical trial in the 1990s that went wrong and led to the death of a patient.
This session asks how we can manage the risks and the potential of medical applications of CRISPR-Cas
- What effects can changing one part of a genome have other parts on other parts of the genome - and can we predict these effects?
- CRISPR-CAS is cheap and accesible: but is that a good thing?
- Can we manage the expectations about what CRISPR-Cas can achieve?
- How do we regulate new technologies - and can the regulation keep up?
Panellists:
- Hilde van de Velde (Centre for Reproductive Medicine)
- Karen Sermon (Research group Reproduction and Genetics)
- Karl Meesters (Patient Representative)
